These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22632603)

  • 21. Human induced pluripotent stem cells and their use in drug discovery for toxicity testing.
    Scott CW; Peters MF; Dragan YP
    Toxicol Lett; 2013 May; 219(1):49-58. PubMed ID: 23470867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary hepatocyte cultures for pharmaco-toxicological studies: at the busy crossroad of various anti-dedifferentiation strategies.
    Fraczek J; Bolleyn J; Vanhaecke T; Rogiers V; Vinken M
    Arch Toxicol; 2013 Apr; 87(4):577-610. PubMed ID: 23242478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microprinting of liver micro-organ for drug metabolism study.
    Chang RC; Emami K; Jeevarajan A; Wu H; Sun W
    Methods Mol Biol; 2011; 671():219-38. PubMed ID: 20967633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The application of 3D cell models to support drug safety assessment: opportunities & challenges.
    Roth A; Singer T
    Adv Drug Deliv Rev; 2014 Apr; 69-70():179-89. PubMed ID: 24378580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stem cell models for drug discovery and toxicology studies.
    Liu W; Deng Y; Liu Y; Gong W; Deng W
    J Biochem Mol Toxicol; 2013 Jan; 27(1):17-27. PubMed ID: 23293059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening methods for influenza antiviral drug discovery.
    Atkins C; Evans CW; White EL; Noah JW
    Expert Opin Drug Discov; 2012 May; 7(5):429-38. PubMed ID: 22435452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using label-free screening technology to improve efficiency in drug discovery.
    Halai R; Cooper MA
    Expert Opin Drug Discov; 2012 Feb; 7(2):123-31. PubMed ID: 22468914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A robust high-throughput sandwich cell-based drug screening platform.
    Zhang S; Tong W; Zheng B; Susanto TA; Xia L; Zhang C; Ananthanarayanan A; Tuo X; Sakban RB; Jia R; Iliescu C; Chai KH; McMillian M; Shen S; Leo H; Yu H
    Biomaterials; 2011 Feb; 32(4):1229-41. PubMed ID: 20971505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of emerging toxicity screens in drug discovery: challenges and implications.
    Wilson AG; Liu X; Kramer JA
    Future Med Chem; 2009 Oct; 1(7):1201-5. PubMed ID: 21426096
    [No Abstract]   [Full Text] [Related]  

  • 31. New technologies and screening strategies for hepatotoxicity: use of in vitro models.
    Dambach DM; Andrews BA; Moulin F
    Toxicol Pathol; 2005; 33(1):17-26. PubMed ID: 15805052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-throughput metabolic stability studies in drug discovery by orthogonal acceleration time-of-flight (OATOF) with analogue-to-digital signal capture (ADC).
    Temesi DG; Martin S; Smith R; Jones C; Middleton B
    Rapid Commun Mass Spectrom; 2010 Jun; 24(12):1730-6. PubMed ID: 20499316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The application of engineered liver tissues for novel drug discovery.
    Lin C; Ballinger KR; Khetani SR
    Expert Opin Drug Discov; 2015 May; 10(5):519-40. PubMed ID: 25840592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug and bioactive molecule screening based on a bioelectrical impedance cell culture platform.
    Ramasamy S; Bennet D; Kim S
    Int J Nanomedicine; 2014; 9():5789-809. PubMed ID: 25525360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Label-free screening assays: a strategy for finding better drug candidates.
    Lunn CA
    Future Med Chem; 2010 Nov; 2(11):1703-16. PubMed ID: 21428840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging technologies and challenges for better and safer drugs.
    Theodosiou M; Amir-Aslani A; Mégarbane B
    Biotechnol Lett; 2014 Apr; 36(4):677-84. PubMed ID: 24243233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging applications of kinetic biomarkers in preclinical and clinical drug development.
    Turner SM; Hellerstein MK
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):115-26. PubMed ID: 15679179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of volume of distribution at steady state in humans: comparison of different approaches.
    Zou P; Zheng N; Yang Y; Yu LX; Sun D
    Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):855-72. PubMed ID: 22591253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of LC-MS techniques and high-throughput approaches used to investigate drug metabolism by cytochrome P450s.
    Youdim KA; Saunders KC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 May; 878(17-18):1326-36. PubMed ID: 20207203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screening out irrelevant cell-based models of disease.
    Horvath P; Aulner N; Bickle M; Davies AM; Nery ED; Ebner D; Montoya MC; Östling P; Pietiäinen V; Price LS; Shorte SL; Turcatti G; von Schantz C; Carragher NO
    Nat Rev Drug Discov; 2016 Nov; 15(11):751-769. PubMed ID: 27616293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.